A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.

NCT03907969 | Completed Phase 1 Results FDA Drug

• 2 other identifiers: D9170C000012018-003688-73
• Study Type: interventional
• Target: 30
• Locations: 2 countries
• Sites: 5

Brief Summary

This is a modular Phase I/IIa, open-label, multi-centre, study of AZD7648 administered orally, either as a monotherapy, or in combination with either cytotoxic chemotherapies or novel anti-cancer agents in participants with advanced malignancies.

Conditions

Advanced Malignancies

Keywords

Safety,; Pharmacokinetics,; Pegylated liposomal doxorubicin,; Dose finding

Outcome Measures

Primary Outcomes (2)

• Number of Patients With Adverse Events or Serious Adverse Events

  Safety and tolerability of AZD7648 when given orally to patients with advanced malignancies, as monotherapy and in combination with anti-cancer agents was assessed.

  From Screening (Day -28) till study drug discontinuation (3.2 years)

• Number of Patients With Dose Limiting Toxicities (DLTs)

  A DLT is defined as an AE that occurs from the first dose of study treatment up to and including Cycle 1, Day 28 (the DLT assessment period) that is assessed as unrelated to the disease, intercurrent illness, or concomitant medications.

  From Screening (Day -28) till study drug discontinuation (3.2 years)

Secondary Outcomes (12)

• Area Under Plasma Concentration-time Curve From Zero to Infinity (AUCinf)

  Monotherapy and Combination therapy: Cycle 0 Day 1 Pre-dose to 72 hours post-dose [each cycle is 28 days]

• Area Under the Plasma Concentration-curve From Zero to the Last Quantifiable Concentration (AUClast)

  Monotherapy and Combination therapy: Cycle 0 Day 1 Pre-dose to 72 hours post-dose (each cycle is 28 days)

• Area Under Plasma Concentration-time Curve in the Dosing Interval τ (AUCτ)

  Monotherapy and Combination therapy: Cycle 0 Day 1 Pre-dose to 72 hours post-dose (each cycle is 28 days)

• Maximum Observed Plasma (Peak) Drug Concentration After Single Dose and Multiple Doses (Cmax)

  Monotherapy: Cycle 0 Day 1 Pre-dose to 72 hours post-dose, Cycle 1 Day 8 Pre-dose to 12 hours post dose; Combination therapy: Cycle 0 Day 1 Pre-dose to 12 hours post dose and Cycle 1 Days 7, 8 Pre-dose to 8 hours post dose (each cycle is 28 days)

• Time to Reach Maximum Plasma Concentration (Tmax)

  Monotherapy: Cycle 0 Day 1 Pre-dose to 72 hours post-dose, Cycle 1 Day 8 Pre-dose to 12 hours post dose; Combination therapy: Cycle 0 Day 1 Pre-dose to 12 hours post dose and Cycle 1 Days 7, 8 Pre-dose to 8 hours post dose (each cycle is 28 days)

Study Arms (2)

Core Module: AZD7648 Monotherapy

EXPERIMENTAL

AZD7648 will be administered orally on an empty stomach

Drug: AZD7648

Combination Module 1: AZD7648 + PLD

EXPERIMENTAL

AZD7648 will be administered in combination with Pegylated liposomal doxorubicin (PLD)

Drug: AZD7648; Drug: PLD

Interventions

AZD7648 DRUG

Core: AZD7648 will be administered orally

Combination Module 1: AZD7648 + PLD; Core Module: AZD7648 Monotherapy

PLD DRUG

The starting dose of PLD is 40 mg/m\^2, administered by intravenous infusion once every 4 weeks, for a maximum of 6 cycles

Also known as: DOXIL, Caelyx

Combination Module 1: AZD7648 + PLD

Eligibility Criteria

• Age: 18 Years - 130 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Capable and willing to give signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).
• Participant must be at least 18 years of age, at the time of signing the ICF.
• Participants must have histological or cytological confirmation of advanced malignancy considered to be suitable for study treatment.
• Eastern cooperative oncology group performance status 0-1.
• Life expectancy greater than 12 weeks.
• Progressive cancer at the time of study entry.
• Pharmacodynamics expansion cohorts: Participants must have at least 1 tumour suitable for biopsy and consent to having biopsies collected.
• Negative pregnancy test (urine or serum) prior to start of dosing for women of childbearing potential.
• Female participants must be post-menopausal, surgically sterile, or using an acceptable method of contraception for the duration of the study (from the time they sign consent) and for 12 weeks after the last dose of study treatment to prevent pregnancy.
• For the duration of the study (from the time they sign consent) and for 12 weeks after the last dose of study treatment, sexually active male participants must be willing to use contraception.
• Post-menopausal is defined as:
• No menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the post-menopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy). However in the absence of 12 months of amenorrhea, a FSH measurement is insufficient.
• Radiation-induced oophorectomy with last menses greater than 12 months ago.
• Chemotherapy-induced menopause with greater than 12 month interval since last menses.
• Surgical sterilisation.

You may not qualify if:

• Any unresolved toxicities from prior therapy common terminology criteria for adverse event (CTCAE) Grade ≥2 (with the exception of alopecia).
• Spinal cord compression or brain metastases unless definitively treated, asymptomatic, stable and not requiring steroids for at least 4 weeks.
• As judged by the Investigator, any evidence of severe or uncontrolled medical conditions including but not limited to:
• Uncontrolled diabetes mellitus, uncontrolled seizures, active infection requiring systemic antibiotics, antifungal or antiviral drugs, severe chronic obstructive pulmonary disease, severe Parkinson's disease, active inflammatory bowel disease, psychiatric condition, active bleeding diatheses, renal transplant, or active infection including any participant with active hepatitis B, hepatitis C or human immunodeficiency virus.
• Any other malignancy which has been active or treated within the past 3 years, with the exception of in situ cancer of the cervix, non-melanoma skin cancer, ductal carcinoma in situ, Stage 1 Grade 1 endometrial carcinoma, or other solid tumours including lymphomas curatively treated with no evidence of disease for ≥5 years.
• Refractory nausea and vomiting or unable to swallow and retain oral medication, chronic gastrointestinal diseases or previous bowel resection with clinically significant sequelae that would preclude adequate absorption of AZD7648, gastrointestinal symptoms CTCAE Grade \>1, history of gastrointestinal ulceration and gastrointestinal haemorrhage within 6 months of first study drug administration.
• Receiving or having received anti-cancer treatment within the following periods prior to the first dose of investigational product:
• (a) Cytotoxic treatment: 3 weeks, (b) Non-cytotoxic drugs: including small molecule investigational products: 3 weeks or 5 half-lives (whichever is longest), (c) Biological products including investigational immuno-oncology agents: 4 weeks, (d) Radiation with a limited field for palliation: 1 week (3 months for radiation to the abdomen or pelvis), (e) Radiation to \>30% of the bone marrow or with a wide field: 4 weeks, (f) Lung radiation: 60 days, (g) Major surgery: 4 weeks; minor surgery or biopsy: 1 week 7. During the 4 weeks prior to the first dose, receiving corticosteroids at a dose of \>10 mg prednisone/day or equivalent for any reason. Ongoing low dose steroids for longer than 3 months (excluding inhalational, nasal, creams, lotions, and gels) are not allowed.
• \. Receiving or having received concomitant medications, herbal supplements and/or foods known to significantly modulate CYP3A4 activity.
• \. Prior exposure to a deoxyribonucleic acid-pharmacokinetics inhibitor or hypersensitivity to any excipient of the product.
• \. Cardiac dysfunction as defined by any of the following within 6 months of study entry:
• (a) Acute myocardial infarction, (b) New York Heart Association Class II/III/IV heart failure, (c) Unstable angina, (d) Unstable cardiac arrhythmias 11. Any of the following cardiac criteria:
• (a) Known reduced left ventricular ejection fraction below the institutional lower limit of normal, (b) Mean resting corrected QT interval (QTc) \>470 milliseconds obtained from 3 electrocardiograms in 24 hours using the Fridericia formula, (c) Any factors that increase the risk of QTc prolongation or arrhythmic events such as hypokalaemia, congenital long QT syndrome, immediate family history of long QT syndrome or unexplained sudden death under 40 years of age 12. Inadequate hematological or organ function 13. Involvement in the planning and/or conduct of the study. 14. Judgement by the Investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.
• \. Previous enrolment in the present study. 16. For female participant only: currently pregnant or breast-feeding. 17. For food effect cohort only: insulin dependent diabetes. 18. History and/or presence of coronavirus disease 2019.

Sponsors & Collaborators

• AstraZeneca: lead
• Parexel: collaborator

Study Sites (5)

Research Site

New Haven, Connecticut, 06510, United States

Location

Research Site

Houston, Texas, 77030, United States

Location

Research Site

London, EC1A 7BE, United Kingdom

Location

Research Site

London, SE1 9RT, United Kingdom

Location

Research Site

Newcastle upon Tyne, NE7 7DN, United Kingdom

Location

Related Publications (1)

• Goldberg FW, Finlay MRV, Ting AKT, Beattie D, Lamont GM, Fallan C, Wrigley GL, Schimpl M, Howard MR, Williamson B, Vazquez-Chantada M, Barratt DG, Davies BR, Cadogan EB, Ramos-Montoya A, Dean E. The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor. J Med Chem. 2020 Apr 9;63(7):3461-3471. doi: 10.1021/acs.jmedchem.9b01684. Epub 2020 Jan 15.

  PMID: 31851518 DERIVED

Related Links

• Protocol redacted
• SAP redacted
• CSR Synopsis redacted

MeSH Terms

Interventions

AZD7648; 1-dodecylpyridoxal; liposomal doxorubicin

Results Point of Contact

• Title: Global Clinical Lead
• Organization: AstraZeneca

information.center@astrazeneca.com

1-877-240-9479

Study Officials

• Dr Timothy Yap

  MD Anderson Cancer Center, 1400 Holcombe Blvd. Houston, Texas, 77030

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Masking Details: This is an open-label study; there will be no blinding.
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 21, 2019
• First Posted: April 9, 2019
• Study Start: October 9, 2019
• Primary Completion: December 7, 2022
• Study Completion: December 7, 2022
• Last Updated: February 6, 2024
• Results First Posted: February 6, 2024

Record last verified: 2024-01

Data Sharing

• IPD Sharing: Will share
• Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• Access Criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Locations

GB (3); US (2)